INFERTILITY PREVENTION PROJECT IPP

1. INFERTILITY PREVENTION PROJECT (IPP) Roxanne Ereth, MPH STD Control Program Manager September 2, 2009

2. Infertility Prevention Project The IPP was established by the CDC and the Office of Population Affairs to reduce the incidence of sexually transmitted diseases that can lead to infertility. Reduce infertility, ectopic pregnancy and chronic pelvic pain Reduce STD-related neonatal infections Reduce further infection

3. Infertility Prevention Project Funded through a portion of the CDC Comprehensive STD Systems Grant Arizona Family Planning Council: Title X (Federal) family planning clinics 40 clinics, 3 juvenile detention centers and mobile vans Title V (HRSA:State) funded family planning clinics 16 sites 11 Juvenile detention, 3 prisons

4. Infertility Prevention Project Title X Family Planning Program Only federal grant program dedicated solely to providing individuals with comprehensive family planning and related preventive health services Designed to provide access to contraceptive services, supplies and information to all who want and need them By law, priority to persons from low-income families

5. Infertility Prevention Project Title V Family Planning Program Federal-State Title V Block Grant Partnership Budget includes Federal funds, State matching funds, local maternal and child health funds, other funds, and program income. For every $4 of Federal funds, at least $3 must be matched with State and local funds.

6. Infertility Prevention ProjectGoal Assess and reduce the prevalence of chlamydial infection and associated complications through: Increased education and training Targeted screening Timely and effective treatment Effective partner referral and treatment Disseminate information to providers and policy makers.

7. Infertility Prevention Project Chlamydial infections cost the U.S. health care system $3 to $4 billion annually. Management of women with PID and its complications Management of infants hospitalized with chlamydial pneumonia

8. Infertility Prevention Project Chlamydia trachomatis: Can cause cervicitis, acute pelvic inflammatory disease (PID), and pre- and postpartum maternal and infant infections. Accounts for 25 – 50% of the 1 million recognized cases of PID in the US each year. ~ 20% of women treated for PID will be infertile Another 18% will experience chronic pelvic pain from the infection ~ 6% will have an ectopic pregnancy Each year, more than 155,000 infants are born to chlamydia-infected mothers. Almost two-thirds of the infants born vaginally to chlamydia-infected mothers become infected during delivery and are at high risk for developing inclusion conjunctivitis and pneumonia. Most common cause of neonatal eye infections and of afebrile interstitial pneumonia in infants less than six months of age

9. Infertility Prevention Project Chlamydial infections are associated with increased susceptibility to and infectiousness of HIV infections. Women and men infected with chlamydia or other STDs are three to five times more likely than non-infected individuals to acquire sexually transmitted HIV. An HIV-infected person who also is infected with an STD may be three to five times more likely to transmit HIV to another through unprotected sexual contact

10. Infertility Prevention Project 70-90% of Chlamydia infections in women are asymptomatic and at least 50% are asymptomatic in men Screen Cost-effective if prevalence is at least 3% in a given population Prevalence monitoring surveillance has indicated that women, less than 25 years of age, screened for chlamydia in family planning settings have a prevalence greater than 3%

11. Infertility Prevention Project Chlamydia trachomatis The cervix of teenage girls and young women is not fully matured: probably more susceptible to infection

12. Infertility Prevention Project

13. Infertility Prevention Project Gonorrhea-related activities are being encouraged. If gonorrhea is seven percent of the sum of gonorrhea and chlamydia among women <26 years of age, then a minimum of seven percent of total IPP testing funds should be devoted to targeted gonorrhea screening Guideline: Add gonorrhea and chlamydia infections among women <26, then divide the number of gonorrhea cases by that total. The percent obtained should be the percent of testing funds that are dedicated to gonorrhea testing.Guideline: Add gonorrhea and chlamydia infections among women <26, then divide the number of gonorrhea cases by that total. The percent obtained should be the percent of testing funds that are dedicated to gonorrhea testing.

14. Infertility Prevention Project Targeted screening All sexually active females who are = 25 years annually: most risk for PID Sex partners of individuals who test positive Due to funding: higher risk populations that include women presenting at STD clinics, in correctional settings and some family planning settings

15. Last 2 rows Include non-IPP sitesLast 2 rows Include non-IPP sites

16. Last 2 rows Include non-IPP sitesLast 2 rows Include non-IPP sites

17. Infertility Prevention Project Screening for women or men Nucleic acid amplification tests are the most sensitive tests for detecting Chlamydia in women. CT urogenital infection can be diagnosed by NAAT using urine or swab specimens collected from the endocervix or vagina. NAAT for C. trachomatis performed on an intraurethral swab or urine specimen is the preferred test for men. Currently use GenProbe’s APTIMA dual test Urine specimen

18. Infertility Prevention Project Recommended Regimens: Azithromycin 1 g orally in a single dose OR Doxycycline 100 mg orally twice a day for 7 days.

19. Infertility Prevention Project No person with Chlamydia trachomatis infection can be considered adequately treated until all of his or her sex partner(s) have also been treated.

20. Infertility Prevention Project

21. Infertility Prevention Project Patient-delivered partner therapy (PDPT): patients take medication/prescription to their partner(s). Pharmacy access programs: partners obtain medication at a participating pharmacy. Field-delivered therapy: health department personnel deliver medication to partners. The following key information and counseling messages must be provided in written format and delivered with the medication or prescription to partner(s): ?? Type of medication, contraindications because of allergy, and possible side effects ?? Partners who have symptoms should seek care as soon as possible ?? Partners should seek a complete STD evaluation in addition to EPT, even without symptoms ?? Partners who have allergies to antibiotics or serious health problems should not take EPT, but should see a health care provider as soon as possible ?? Partners should abstain from sex for at least 7 days after treatment and until 7 days after all partners have been treated, to decrease the risk of reinfectionThe following key information and counseling messages must be provided in written format and delivered with the medication or prescription to partner(s): ?? Type of medication, contraindications because of allergy, and possible side effects ?? Partners who have symptoms should seek care as soon as possible ?? Partners should seek a complete STD evaluation in addition to EPT, even without symptoms ?? Partners who have allergies to antibiotics or serious health problems should not take EPT, but should see a health care provider as soon as possible ?? Partners should abstain from sex for at least 7 days after treatment and until 7 days after all partners have been treated, to decrease the risk of reinfection

22. Infertility Prevention Project Test of Cure Non-pregnant patients do not need to be retested for chlamydia after completing treatment with a recommended or alternative regimen unless compliance is in question, symptoms persist or re-infection is suspected.

23. Infertility Prevention Project Re-Testing 3 months following treatment for detecting re-infection: occurs in 10-25% of persons NAATs identify nuclear material from chlamydia organisms Positive tests may occur up to 4 weeks following adequate treatment. Retesting should not be performed prior to 4 weeks post-treatment. because of residual nuclear material present in host cells still being shed from genital tract tissues. The retesting of patients optimally at 3 months after initial treatment for chlamydia or gonorrhea, or whenever they next seek care within the 3-12 months following treatment, is standard policy for all IPP project areas in Region IX. (Note: For purposes of program evaluation, Region IX IPP analyzes retest estimate data obtained from tests performed 2 through 11 months after the date of the first positive test.) In addition to counseling patients about the importance of retesting, IPP delegate agencies are strongly encouraged to choose and institute an active protocol designed to maximize their retesting rates.because of residual nuclear material present in host cells still being shed from genital tract tissues. The retesting of patients optimally at 3 months after initial treatment for chlamydia or gonorrhea, or whenever they next seek care within the 3-12 months following treatment, is standard policy for all IPP project areas in Region IX. (Note: For purposes of program evaluation, Region IX IPP analyzes retest estimate data obtained from tests performed 2 through 11 months after the date of the first positive test.) In addition to counseling patients about the importance of retesting, IPP delegate agencies are strongly encouraged to choose and institute an active protocol designed to maximize their retesting rates.

24. Approximately 26,000 tests run at ASLS No longer has the capacity Can only run APTIMA (NAAT) More sensitive More expensive Infertility Prevention Project

25. Infertility Prevention Project Future plans/options RFP for private laboratory posted Proposals have been received and being evaluated Sites not under AZ Family Planning Council (Title V, Corrections) must have MOU Ensure specimens submitted meet criteria Discontinue sites with low prevalence or who don’t abide by criteria Review single test option rather than CT and GC Review restrictions for males

26. Infertility Prevention Project Region IX Guidelines http://www.centerforhealthtraining.org/projects/documents/2009%20Region%20IX%20Chlamydia%20Clinical%20Guidelines.pdf